VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

Company Performance - VAXART, INC. reported a quarterly loss of $0.07 per share, which was better than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of +22.22% [1] - The company posted revenues of $39.73 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 1,206.91%, compared to revenues of $6.4 million in the same quarter last year [2] - Over the last four quarters, VAXART has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - VAXART shares have declined approximately 42.6% since the beginning of the year, while the S&P 500 has gained 9.6% [3] - The current Zacks Rank for VAXART is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $3.29 million, and for the current fiscal year, it is -$0.28 on revenues of $24.15 million [7] - The outlook for the Medical - Drugs industry, to which VAXART belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]